Tyra Biosciences, Inc.

TYRA Nasdaq SEC CIK 1863127
Follow Tyra Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$51.1M −71.2% vs same quarter last year
EPS, diluted −$0.74 −48% vs same quarter last year
Operating cash flow −$32.2M −43.9% vs same quarter last year
Operating income −$54.9M −66.6% vs same quarter last year
Net income by quarter
−$25.6M
−$28.1M
−$28.1M
−$29.9M
−$33.8M
−$39.3M
−$45.6M
−$51.1M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$150M−$100M−$50M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$119.9M
FY24−$86.5M
FY23−$69.1M
FY22−$55.3M
FY21−$26.3M
FY20−$9.3M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$100M−$75M−$50M−$25M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$95.3M
FY24−$70.4M
FY23−$50.9M
FY22−$50.8M
FY21−$24.4M
FY20−$8.1M
FY19-